CME Information: 1.0 Credit
Expiration Date: October 31, 2019
You must be logged in and own this product in order to post comments.
The CME exam has a error in it the questions about the objectives is referencing TMVR not Fabry's disease.
VERY DIFFICULT QUESTIONS. " ANSWERS BURIED WITHIN TEXT". I FELT THE TEST WERE MUCH TO DIFFICULT FOR 1 CME
Resubmit... ? Did article completely upload?.
Echocardiographic Assessment of Patients with Fabry Disease
CME Information: 1.00 credits
Release date: June 2018 Valid through: October 2019
Introduction/Statement of Need:
Fabry disease is an X-linked lysosomal storage disorder that results from a deficiency of a-galactosidase A. Increased left ventricular wall thickness has been the most commonly described cardiovascular manifestation of the disease. However, a variety of other structural and functional abnormalities have also been reported. Echocardiography is an effective noninvasive method of assessing the cardiac involvement of Fabry disease. A more precise and comprehensive characterization of Fabry cardiomyopathy using conventional and novel echocardiographic techniques may lead to earlier diagnosis, more accurate prognostication, and timely treatment.
The aim of this review is to provide a comprehensive overview of the structural and functional abnormalities on echocardiography that have thus far been described in patients with Fabry disease and to highlight potential areas that would benefit from further research.
This activity is designed for all cardiac sonographers and cardiovascular physicians with a primary interest and knowledge base in the field of echocardiography; in addition, residents, researchers, clinicians, intensivists, and other medical professionals.
At the end of this article the reader will better be able to:
1. Review the echocardiographic assessment of patients with Fabry disease
2. Define structural function in patients with Fabry disease
3. Recognize the effect of ERT on cardiac structure and function
The American Society of Echocardiography is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American Society of Echocardiography designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1.00 MOC point in the American Board of Internal Medicine's (ABIM). Participants will earn MOC point’s equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
ARDMS, CCI and Sonography Canada recognize ASE’s certificates and have agreed to honor the credit hours toward their registry requirements for sonographers.
The American Society of Echocardiography is committed to ensuring that its educational mission and all sponsored educational programs are not influenced by the special interests of any corporation or individual, and its mandate is to retain only those authors whose financial interests can be effectively resolved to maintain the goals and educational integrity of the activity. While a monetary or professional affiliation with a corporation does not necessarily influence an author’s presentation, the Essential Areas and policies of the ACCME require that any relationships that could possibly conflict with the educational value of the activity be resolved prior to publication and disclosed to the audience. Disclosures of faculty and commercial support relationships, if any, have been indicated.
Darwin F. Yeung, MD, Sandra Sirrs, MD, Michael Y. C. Tsang, MD, Kenneth Gin, MD, Christina Luong, MD, Joe Jue, MD, Parvathy Nair, MD, Pui K. Lee, MD and Teresa S. M. Tsang, MD, Vancouver, British Columbia, Canada
According to ACCME policy, ASE implemented mechanisms to resolve all conflicts of interest prior to the planning and implementation of this activity.
The following author(s) reports actual or potential conflicts of interest in relation to this document:
Sandra Sirrs, MD: Sonofi Genzyme – Consultant/Advisor, Corporate Research Collaboration (including trials/product testing)/ Shire Human Genetics Therapies – Corporate Research Collaboration (including trials/product testing), Actelion – Consultant/Advisor).
The following authors reported no actual or potential conflicts of interest in relation to this document:
Darwin F. Yeung, MD, Michael Y. C. Tsang, MD, Kenneth Gin, MD, Christina Luong, MD, Joe Jue, MD, Parvathy Nair, MD, Pui K. Lee, MD and Teresa S. M. Tsang, MD.
The following ACCME reviewers, ASE Staff and CME editors reported no actual or potential conflicts of interest in relation to this document:
Priscilla Peters, and Christina LaFuria
The following ACCME reviewers, ASE Staff and CME editors reported relationships with one or more commercial interests:
Method of Participation: Online Only
Estimated Time to Complete this Activity: 1 hour
Receiving CME Credit:
To receive online CME credit for this activity, read the full activity then complete the posttest and evaluation. A score of 70% or higher is required for successful completion. You will be able to print your CME certificate immediately following successful completion of the posttest and evaluation.
You will need a compatible browser like Mozilla FireFox, Google Chrome or safari to view the content. Internet Explorer may not work.
This report is made available by ASE as a courtesy reference source for members. This report contains recommendations only and should not be used as the sole basis to make medical practice decisions or for disciplinary action against any employee. The statements and recommendations contained in this report are primarily based on the opinions of experts, rather than on scientifically verified data. ASE makes no express or implied warranties regarding the completeness or accuracy of the information in this report, including the warranty of merchantability or fitness for a particular purpose. In no event shall ASE be liable to you, your patients, or any other third parties for any decision made or action taken by you or such other parties in reliance on this information. Nor does your use of this information constitute the offering of medical advice by ASE or create any physician patient relationship between ASE and your patients or anyone else.
1. Zarate YA, Hopkin RJ. Fabry’s disease. Lancet 2008;372:1427-35.
2. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999;281:249-54.
3. Houge G, Skarbovik AJ. Fabry disease—a diagnostic and therapeutic chal- lenge. Tidsskr Nor Laegeforen 2005;125:1004-6.
4. Biegstraaten M, Arngrimsson R, Barbey F, Boks L, Cecchi F, Deegan PB, et al. Recommendations for initiation and cessation of enzyme replace- ment therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet J Rare Dis 2015;10:36.
5. Jurcut R. Third in a series on Fabry disease: what is the importance of im- aging in Fabry disease? E-J Cardiol Pract 2016;14:9.
6. Niemann MWF. Echocardiography in Fabry disease. Cardiogenetics 2013;3:e3.
7. Pieroni M, Chimenti C, Russo A, Russo MA, Maseri A, Frustaci A. Tissue Doppler imaging in Fabry disease. Curr Opin Cardiol 2004;19:452-7.
8. Pieroni M. Echocardiographic assessment of Fabry cardiomyopathy: early diagnosis and follow-up. J Am Soc Echocardiogr 2011;24:1033-6.
9. Pompen AW, Ruiter M, Wyers HJ. Angiokeratoma corporis diffusum (universale) Fabry, as a sign of an unknown internal disease; two autopsy reports. Acta Med Scand 1947;128:234-55.
10. Karr WJ Jr. Fabry’s disease (angiokeratoma corporis diffusum universale). An unusual syndrome with multisystem involvement and unique skin manifestations. Am J Med 1959;27:829-35.
11. Bass JL, Shrivastava S, Grabowski GA, Desnick RJ, Moller JH. The M- mode echocardiogram in Fabry’s disease. Am Heart J 1980;100:807-12.
12. Linhart A, Palecek T, Bultas J, Ferguson JJ, Hrudova J, Karetova D, et al. New insights in cardiac structural changes in patients with Fabry’s disease. Am Heart J 2000;139:1101-8.
13. Wu JC, Ho CY, Skali H, Abichandani R, Wilcox WR, Banikazemi M, et al. Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and alpha-galactosidase A activity. Eur Heart J 2010;31:1088-97.
14. Tanaka H, Adachi K, Yamashita Y, Toshima H, Koga Y. Four cases of Fabry’s disease mimicking hypertrophic cardiomyopathy. J Cardiol 1988;18:705-18.
15. Elleder M, Bradova V, Smid F, Budesinsky M, Harzer K, Kustermann-Kuhn B, et al. Cardiocyte storage and hypertrophy as a sole manifestation of Fabry’s disease. Report on a case simulating hypertrophic non- obstructive cardiomyopathy. Virchows Arch A Pathol Anat Histopathol 1990;417:449-55.
16. Chimenti C, Ricci R, Pieroni M, Natale L, Russo MA, Frustaci A. Cardiac variant of Fabry’s disease mimicking hypertrophic cardiomyopathy. Car- diologia 1999;44:469-73.
17. Sachdev B, Takenaka T, Teraguchi H, Tei C, Lee P, McKenna WJ, et al. Prevalence of Anderson-Fabry disease in male patients with late onset hy- pertrophic cardiomyopathy. Circulation 2002;105:1407-11.
18. Thomas L, Sadick N. A case of Fabry disease mimicking hypertrophic car- diomyopathy. Heart Lung Circ 2004;13:188-90.
19. Cianciulli TF, Saccheri MC, Fernandez SP, Fernandez CC, Rozenfeld PA, Kisinovsky I. Apical left ventricular hypertrophy and mid-ventricular obstruction in Fabry disease. Echocardiography 2015;32:860-3.
20. Yano T, Oshima H, Miki T, Tanaka M, Muranaka A, Osanami A, et al. Late gadolinium enhancement image masquerading as hypertrophic car- diomyopathy in Fabry disease receiving enzyme replacement therapy. Int J Cardiol 2016;203:136-7.
21. Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, Tahara M, et al. An atypical variant of Fabry’s disease in men with left ventricular hyper- trophy. N Engl J Med 1995;333:288-93.
22. Seward JB, Casaclang-Verzosa G. Infiltrative cardiovascular diseases: car- diomyopathies that look alike. J Am Coll Cardiol 2010;55:1769-79.
23. Sadick N, Thomas L. Cardiovascular manifestations in Fabry disease: a clinical and echocardiographic study. Heart Lung Circ 2007;16:200-6.
24. Yanagawa Y, Sakuraba H. Cardiovascular manifestations in Fabry’s dis- ease—age-related changes in hemizygotes and heterozygotes. Acta Pae- diatr Jpn 1988;30:38-48.
25. Linhart A, Kampmann C, Zamorano JL, Sunder-Plassmann G, Beck M, Mehta A, et al. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J 2007;28: 1228-35.
26. Goldman ME, Cantor R, Schwartz MF, Baker M, Desnick RJ. Echocardio- graphic abnormalities and disease severity in Fabry’s disease. J Am Coll Cardiol 1986;7:1157-61.
27. Kampmann C, Linhart A, Baehner F, Palecek T, Wiethoff CM, Miebach E, et al. Onset and progression of the Anderson-Fabry disease related cardiomyopathy. Int J Cardiol 2008;130:367-73.
28. Patel MR, Cecchi F, Cizmarik M, Kantola I, Linhart A, Nicholls K, et al. Cardiovascular events in patients with Fabry disease natural history data from the Fabry registry. J Am Coll Cardiol 2011;57:1093-9.
29. Agarwal A, Malik A, DeFranco AC, Tajik AJ. Left ventricular apical aneu- rysm: a novel phenotype of Fabry’s disease. Eur Heart J Cardiovasc Imag- ing 2014;15:585.
30. Poulin MF, Shah A, Trohman RG, Madias C. Advanced Anderson-Fabry disease presenting with left ventricular apical aneurysm and ventricular tachycardia. World J Clin Cases 2015;3:519-24.
31. Azevedo O, Gaspar P, Sa Miranda C, Cunha D, Medeiros R, Lourenco A. Left ventricular noncompaction in a patient with Fabry disease: overdiag- nosis, morphological manifestation of Fabry disease or two unrelated rare conditions in the same patient? Cardiology 2011;119:155-9.
32. Martins E, Pinho T, Carpenter S, Leite S, Garcia R, Madureira A, et al. His- topathological evidence of Fabry disease in a female patient with left ven- tricular noncompaction. Rev Port Cardiol 2014;33:565.e1-6.
33. Pieroni M, Chimenti C, De Cobelli F, Morgante E, Del Maschio A, Gaudio C, et al. Fabry’s disease cardiomyopathy: echocardiographic detection of endomyocardial glycosphingolipid compartmentalization. J Am Coll Cardiol 2006;47:1663-71.
34. Kounas S, Demetrescu C, Pantazis AA, Keren A, Lee PJ, Hughes D, et al. The binary endocardial appearance is a poor discriminator of Anderson- Fabry disease from familial hypertrophic cardiomyopathy. J Am Coll Car- diol 2008;51:2058-61.
35. Kovacevic-Preradovic T, Zuber M, Attenhofer Jost CH, Widmer U, Seifert B, Schulthess G, et al. Anderson-Fabry disease: long-term echocardiographic follow-up under enzyme replacement therapy. Eur J Echocardiogr 2008;9:729-35.
36. Koskenvuo JW, Engblom E, Kantola IM, Hartiala JJ, Saraste A, Kiviniemi TO, et al. Echocardiography in Fabry disease: diagnostic value of endocardial border binary appearance. Clin Physiol Funct Imaging 2009;29:177-80.
37. Mundigler G, Gaggl M, Heinze G, Graf S, Zehetgruber M, Lajic N, et al. The endocardial binary appearance (‘‘binary sign’’) is an unreliable marker for echocardiographic detection of Fabry disease in patients with left ven- tricular hypertrophy. Eur J Echocardiogr 2011;12:744-9.
38. Weidemann F, Wanner C, Breunig F. Nomen est omen. Fabry disease. Eur J Echocardiogr 2008;9:831-2.
39. Hoigne P, Attenhofer Jost CH, Duru F, Oechslin EN, Seifert B, Widmer U, et al. Simple criteria for differentiation of Fabry disease from amyloid heart disease and other causes of left ventricular hypertrophy. Int J Car- diol 2006;111:413-22.
40. Linhart A, Lubanda JC, Palecek T, Bultas J, Karetova D, Ledvinova J, et al. Cardiac manifestations in Fabry disease. J Inherit Metab Dis 2001; 24(suppl 2):75-83.
41. Strotmann J, Weidemann F, Breunig F, Knoll A, Wanner C, Ertl G. Morbus Fabry of the heart. Why should cardiologists care? Z Kardiol 2005;94: 557-63.
42. Niemann M, Liu D, Hu K, Herrmann S, Breunig F, Strotmann J, et al. Prominent papillary muscles in Fabry disease: a diagnostic marker? Ultra- sound Med Biol 2011;37:37-43.
43. Hillsley RE, Hernandez E, Steenbergen C, Bashore TM, Harrison JK. In- herited restrictive cardiomyopathy in a 74-year-old woman: a case of Fabry’s disease. Am Heart J 1995;129:199-202.
44. Kampmann C, Baehner FA, Whybra C, Bajbouj M, Baron K, Knuf M, et al. The right ventricle in Fabry disease. Acta Paediatr Suppl 2005; 94:15-8.
45. Palecek T, Dostalova G, Kuchynka P, Karetova D, Bultas J, Elleder M, et al. Right ventricular involvement in Fabry disease. J Am Soc Echocar- diogr 2008;21:1265-8.
46. Niemann M, Breunig F, Beer M, Herrmann S, Strotmann J, Hu K, et al. The right ventricle in Fabry disease: natural history and impact of enzyme replacement therapy. Heart 2010;96:1915-9.
47. Graziani F, Laurito M, Pieroni M, Pennestri F, Lanza GA, Coluccia V, et al. Right ventricular hypertrophy, systolic function, and disease severity in Anderson-Fabry disease: an echocardiographic study. J Am Soc Echocar- diogr 2017;30:282-91.
48. Weidemann F, Breunig F, Beer M, Sandstede J, Stork S, Voelker W, et al. The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J 2005;26:1221-7.
49. Morris DA, Blaschke D, Canaan-Kuhl S, Krebs A, Knobloch G, Walter TC, et al. Global cardiac alterations detected by speckle- tracking echocardiography in Fabry disease: left ventricular, right ventric- ular, and left atrial dysfunction are common and linked to worse symp- tomatic status. Int J Cardiovasc Imaging 2015;31:301-13.
50. Ferrans VJ, Hibbs RG, Burda CD. The heart in Fabry’s disease. A histo- chemical and electron microscopic study. Am J Cardiol 1969;24:95-110.
51. Becker AE, Schoorl R, Balk AG, van der Heide RM. Cardiac manifesta- tions of Fabry’s disease. Report of a case with mitral insufficiency and electrocardiographic evidence of myocardial infarction. Am J Cardiol 1975;36:829-35.
52. Desnick RJ, Blieden LC, Sharp HL, Hofschire PJ, Moller JH. Cardiac valvular anomalies in Fabry disease. Clinical, morphologic, and biochem- ical studies. Circulation 1976;54:818-25.
53. von Scheidt W, Eng CM, Fitzmaurice TF, Erdmann E, Hubner G, Olsen EG, et al. An atypical variant of Fabry’s disease with manifestations confined to the myocardium. N Engl J Med 1991;324:395-9.
54. Choi S, Seo H, Park M, Kim J, Hwang S, Kwon K, et al. Fabry disease with aortic regurgitation. Ann Thorac Surg 2009;87:625-8.
55. Senechal M, Germain DP. Fabry disease: a functional and anatomical study of cardiac manifestations in 20 hemizygous male patients. Clin Genet 2003;63:46-52.
56. Kramer J, Niemann M, Liu D, Hu K, Machann W, Beer M, et al. Two-dimensional speckle tracking as a non-invasive tool for identification of myocardial fibrosis in Fabry disease. Eur Heart J 2013;34:1587-96.
57. Pieroni M, Chimenti C, Ricci R, Sale P, Russo MA, Frustaci A. Early detec- tion of Fabry cardiomyopathy by tissue Doppler imaging. Circulation 2003;107:1978-84.
58. Boyd AC, Lo Q, Devine K, Tchan MC, Sillence DO, Sadick N, et al. Left atrial enlargement and reduced atrial compliance occurs early in Fabry cardiomyopathy. J Am Soc Echocardiogr 2013;26:1415-23.
59. Pichette M, Serri K, Page M, Di LZ, Bichet DG, Poulin F. Impaired left atrial function in Fabry disease: a longitudinal speckle-tracking echocardi- ography study. J Am Soc Echocardiogr 2017;30:170-9.e2.
60. Sakuraba H, Yanagawa Y, Igarashi T, Suzuki Y, Suzuki T, Watanabe K, et al. Cardiovascular manifestations in Fabry’s disease. A high incidence of mitral valve prolapse in hemizygotes and heterozygotes. Clin Genet 1986;29:276-83.
61. Nagao Y, Nakashima H, Fukuhara Y, Shimmoto M, Oshima A, Ikari Y, et al. Hypertrophic cardiomyopathy in late-onset variant of Fabry disease with high residual activity of alpha-galactosidase A. Clin Genet 1991;39: 233-7.
62. Brokalaki EI, Hentschke M, Grabbe S, Jansen T. Fabry disease in a female patient due to a de novo point mutation at position 691 of exon 5. Eur J Med Res 2006;11:306-8.
63. Galanos J, Nicholls K, Grigg L, Kiers L, Crawford A, Becker G. Clinical features of Fabry’s disease in Australian patients. Intern Med J 2002; 32:575-84.
64. Weidemann F, Strotmann JM, Niemann M, Herrmann S, Wilke M, Beer M, et al. Heart valve involvement in Fabry cardiomyopathy. Ultra- sound Med Biol 2009;35:730-5.
65. Iwase M, Yamauchi K, Maeda M, Aoki T, Yokota M, Hayashi H, et al. Echocardiographic findings in a case of Fabry’s disease with aortic regur- gitation and complete AV block, and in his family members. J Cardiol 1988;18:589-98.
66. Masugata H, Senda S, Goda F, Yamagami A, Okuyama H, Kohno T, et al. Decline of plasma brain natriuretic peptide during enzyme replacement therapy in a female patient with heterozygous Fabry’s disease. Tohoku J Exp Med 2009;217:169-74.
67. Marci M, Duro G, Tuttolomondo A, Pinto A, Cirrincione V, Sanfilippo N. Delayed diagnosis of Fabry disease presenting as myocardial ischaemia. Hellenic J Cardiol 2012;53:485.
68. Fernandez J, Sigurdsson G, Farivar RS. Cardiac surgery in patients with Fabry’s disease: review of literature. J Card Surg 2012;27:478-80.
69. Barbey F, Qanadli SD, Juli C, Brakch N, Palacek T, Rizzo E, et al. Aortic remodelling in Fabry disease. Eur Heart J 2010;31:347-53.
70. Shah JS, Lee P, Hughes D, Thaman R, Sachdev B, Pellerin D, et al. The natural history of left ventricular systolic function in Anderson-Fabry dis- ease. Heart 2005;91:533-4.
71. Cantor WJ, Butany J, Iwanochko M, Liu P. Restrictive cardiomyopathy secondary to Fabry’s disease. Circulation 1998;98:1457-9.
72. Spinelli L, Pisani A, Sabbatini M, Petretta M, Andreucci MV, Procaccini D, et al. Enzyme replacement therapy with agalsidase beta im- proves cardiac involvement in Fabry’s disease. Clin Genet 2004;66: 158-65.
73. Niemann M, Breunig F, Beer M, Hu K, Liu D, Emmert A, et al. Tei index in Fabry disease. J Am Soc Echocardiogr 2011;24:1026-32.
74. Kawano M, Takenaka T, Otsuji Y, Teraguchi H, Yoshifuku S, Yuasa T, et al. Significance of asymmetric basal posterior wall thinning in patients with cardiac Fabry’s disease. Am J Cardiol 2007;99:261-3.
75. Nagueh SF, Bachinski LL, Meyer D, Hill R, Zoghbi WA, Tam JW, et al. Tis- sue Doppler imaging consistently detects myocardial abnormalities in pa- tients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy. Circulation 2001;104:128-30.
76. Ho CY, Sweitzer NK, McDonough B, Maron BJ, Casey SA, Seidman JG, et al. Assessment of diastolic function with Doppler tissue imaging to pre- dict genotype in preclinical hypertrophic cardiomyopathy. Circulation 2002;105:2992-7.
77. Urheim S, Edvardsen T, Torp H, Angelsen B, Smiseth OA. Myocardial strain by Doppler echocardiography. Validation of a new method to quantify regional myocardial function. Circulation 2000;102:1158-64.
78. Weidemann F, Breunig F, Beer M, Sandstede J, Turschner O, Voelker W, et al. Improvement of cardiac function during enzyme replacement ther- apy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 2003;108:1299-301.
79. Chimenti C, Pieroni M, Morgante E, Antuzzi D, Russo A, Russo MA, et al. Prevalence of Fabry disease in female patients with late-onset hypertro- phic cardiomyopathy. Circulation 2004;110:1047-53.
80. Fiuza M, Avo LB, Oliveira EI, Goncalves S, Lopes MG. Detection of pre- clinical left ventricular dysfunction in Fabry disease: the contribution of tissue Doppler. Rev Port Cardiol 2006;25:613-37.
81. Palecek T, Linhart A, Lubanda JC, Magage S, Karetova D, Bultas J, et al. Early diastolic mitral annular velocity and color M-mode flow propaga- tion velocity in the evaluation of left ventricular diastolic function in pa- tients with Fabry disease. Heart Vessels 2006;21:13-9.
82. Toro R, Perez-Isla L, Doxastaquis G, Barba MA, Gallego AR, Pintos G, et al. Clinical usefulness of tissue Doppler imaging in predicting preclin- ical Fabry cardiomyopathy. Int J Cardiol 2009;132:38-44.
83. Niemann M, Herrmann S, Hu K, Breunig F, Strotmann J, Beer M, et al. Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment. JACC Cardiovasc Imaging 2011;4:592-601.
84. Moon JC, Sachdev B, Elkington AG, McKenna WJ, Mehta A, Pennell DJ, et al. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 2003;24:2151-5.
85. Frustaci A, Chimenti C, Ricci R, Natale L, Russo MA, Pieroni M, et al. Improvement in cardiac function in the cardiac variant of Fabry’s disease with galactose-infusion therapy. N Engl J Med 2001;345:25-32.
86. Baehner F, Kampmann C, Whybra C, Miebach E, Wiethoff CM, Beck M. Enzyme replacement therapy in heterozygous females with Fabry dis- ease: results of a phase IIIB study. J Inherit Metab Dis 2003;26:617-27.
87. Beck M, Ricci R, Widmer U, Dehout F, de Lorenzo AG, Kampmann C, et al. Fabry disease: overall effects of agalsidase alfa treatment. Eur J Clin Invest 2004;34:838-44.
88. Hughes DA, Elliott PM, Shah J, Zuckerman J, Coghlan G, Brookes J, et al. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 2008;94:153-8.
89. De Cobelli F, Esposito A, Belloni E, Pieroni M, Perseghin G, Chimenti C, et al. Delayed-enhanced cardiac MRI for differentiation of Fabry’s dis- ease from symmetric hypertrophic cardiomyopathy. AJR Am J Roent- genol 2009;192:W97-102.
90. Imbriaco M, Pisani A, Spinelli L, Cuocolo A, Messalli G, Capuano E, et al. Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study. Heart 2009;95:1103-7.
91. Kampmann C, Linhart A, Devereux RB, Schiffmann R. Effect of agalsidase alfa replacement therapy on Fabry disease-related hypertrophic cardiomy- opathy: a 12- to 36-month, retrospective, blinded echocardiographic pooled analysis. Clin Ther 2009;31:1966-76.
92. Mehta A, Beck M, Elliott P, Giugliani R, Linhart A, Sunder-Plassmann G, et al. Enzyme replacement therapy with agalsidase alfa in patients with Fabry’s disease: an analysis of registry data. Lancet 2009;374:1986-96.
93. Weidemann F, Niemann M, Breunig F, Herrmann S, Beer M, Stork S, et al. Long-term effects of enzyme replacement therapy on Fabry cardio- myopathy: evidence for a better outcome with early treatment. Circula- tion 2009;119:524-9.
94. Beer M, Weidemann F, Breunig F, Knoll A, Koeppe S, Machann W, et al. Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry’s cardiomyopathy. Am J Cardiol 2006;97:1515-8.
95. Weidemann F, Niemann M, Herrmann S, Kung M, Stork S, Waller C, et al. A new echocardiographic approach for the detection of non- ischaemic fibrosis in hypertrophic myocardium. Eur Heart J 2007;28: 3020-6.
96. Garceau P, Nguyen ET, Carasso S, Ross H, Pendergrast J, Moravsky G, et al. Quantification of myocardial iron deposition by two-dimensional speckle tracking in patients with beta-thalassaemia major and Blackfan- Diamond anaemia. Heart 2011;97:388-93.
97. Gruner C, Verocai F, Carasso S, Vannan MA, Jamorski M, Clarke JT, et al. Systolic myocardial mechanics in patients with Anderson-Fabry disease with and without left ventricular hypertrophy and in comparison to non- obstructive hypertrophic cardiomyopathy. Echocardiography 2012;29: 810-7.
98. Labombarda F, Saloux E, Milesi G, Bienvenu B. Loss of base-to-apex circumferential strain gradient: a specific pattern of Fabry cardiomyopa- thy? Echocardiography 2017;34:504-10.
99. Moon JC, Sheppard M, Reed E, Lee P, Elliott PM, Pennell DJ. The histo- logical basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease. J Cardiovasc Magn Reson 2006;8:479-82.
100. Saccheri MC, Cianciulli TF, Lax JA, Gagliardi JA, Caceres GL, Quarin AE, et al. Two-dimensional speckle tracking echocardiography for early detection of myocardial damage in young patients with Fabry disease. Echocardiography 2013;30:1069-77.
101. Deva DP, Hanneman K, Li Q, Ng MY, Wasim S, Morel C, et al. Cardio- vascular magnetic resonance demonstration of the spectrum of morpho- logical phenotypes and patterns of myocardial scarring in Anderson- Fabry disease. J Cardiovasc Magn Reson 2016;18:14.
102. Shanks M, Thompson RB, Paterson ID, Putko B, Khan A, Chan A, et al. Systolic and diastolic function assessment in Fabry disease patients using speckle-tracking imaging and comparison with conventional echocardio- graphic measurements. J Am Soc Echocardiogr 2013;26:1407-14.
103. Sirrs S, Bichet D, Iwanochko M, Khan A, Moore D, Oudit G, et al. Cana- dian Fabry disease treatment guidelines. Available at: http://www.garrod. ca/wp-content/uploads/Canadian-FD-Treatment-Guidelines-2016.pdf; 2016.
104. Zamorano J, Serra V, Perez de Isla L, Feltes G, Calli A, Barbado FJ, et al. Usefulness of tissue Doppler on early detection of cardiac disease in Fabry patients and potential role of enzyme replacement therapy (ERT) for avoiding progression of disease. Eur J Echocardiogr 2011;12: 671-7.
105. Vedder AC, Linthorst GE, Houge G, Groener JE, Ormel EE, Bouma BJ, et al. Treatment of Fabry disease: outcome of a compar- ative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg. PLoS One 2007;2:e598.
106. Madsen CV, Bundgaard H, Rasmussen AK, Sorensen SS, Petersen JH, Kober L, et al. Echocardiographic and clinical findings in patients with Fabry disease during long-term enzyme replacement therapy: a nation- wide Danish cohort study. Scand Cardiovasc J 2017;51:207-16.
107. Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 2007;146:77-86.
108. Weidemann F, Niemann M, Stork S, Breunig F, Beer M, Sommer C, et al. Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications. J Intern Med 2013;274:331-41.